{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:51:25Z","timestamp":1776408685526,"version":"3.51.2"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06955-9","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T05:19:30Z","timestamp":1775107170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Correspondance: Venetoclax combined with FLAG-based chemotherapy induces rapid and deep responses in early T-cell precursor lymphoblastic leukemia\/lymphoma. Report of two cases and review of the literature"],"prefix":"10.1007","volume":"105","author":[{"given":"Julien","family":"Dereme","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandine","family":"Segot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitja","family":"Nabergoj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natacha","family":"Dewarrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Basset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Blum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerasimos","family":"Tsilimidos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"15","key":"6955_CR1","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","volume":"127","author":"N Jain","year":"2016","unstructured":"Jain N et al (2016) Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: a high-risk subtype. Blood 127(15):1863\u20131869","journal-title":"Blood"},{"key":"6955_CR2","doi-asserted-by":"publisher","first-page":"1025885","DOI":"10.3389\/fonc.2022.1025885","volume":"12","author":"J Chen","year":"2022","unstructured":"Chen J et al (2022) Comparison of characteristics and outcomes on ETP-ALL\/LBL and non-ETP ALL patients receiving allogeneic hematopoietic stem cell transplantation. Front Oncol 12:1025885","journal-title":"Front Oncol"},{"issue":"6","key":"6955_CR3","doi-asserted-by":"publisher","first-page":"481 e1","DOI":"10.1016\/j.jtct.2021.02.032","volume":"27","author":"S Liu","year":"2021","unstructured":"Liu S et al (2021) Early T-cell precursor acute lymphoblastic leukemia and T\/myeloid mixed phenotype acute leukemia possess overlapping characteristics and both benefit from CAG-like regimens and allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther 27(6):481 e1-481 e7","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"6955_CR4","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36(7):1703\u20131719","journal-title":"Leukemia"},{"issue":"7","key":"6955_CR5","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720\u20131748","journal-title":"Leukemia"},{"key":"6955_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14081873","author":"E Genesca","year":"2022","unstructured":"Genesca E, la Starza R (2022) Early T-cell precursor ALL and beyond: immature and ambiguous lineage T-ALL subsets. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14081873","journal-title":"Cancers (Basel)"},{"issue":"3","key":"6955_CR7","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41375-020-0965-z","volume":"35","author":"J Bond","year":"2021","unstructured":"Bond J et al (2021) A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis. Leukemia 35(3):724\u2013736","journal-title":"Leukemia"},{"issue":"9","key":"6955_CR8","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","volume":"4","author":"TN Chonghaile","year":"2014","unstructured":"Chonghaile TN et al (2014) Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov 4(9):1074\u20131087","journal-title":"Cancer Discov"},{"issue":"1","key":"6955_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/1078-0432.CCR-23-2159","volume":"30","author":"A Pinton","year":"2024","unstructured":"Pinton A et al (2024) PHF6-altered T-ALL harbor epigenetic repressive switch at bivalent promoters and respond to 5-azacitidine and venetoclax. Clin Cancer Res 30(1):94\u2013105","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6955_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053190","volume":"8","author":"M Neumann","year":"2013","unstructured":"Neumann M et al (2013) FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One 8(1):e53190","journal-title":"PLoS One"},{"issue":"1","key":"6955_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01638-7","volume":"25","author":"F Xu","year":"2025","unstructured":"Xu F et al (2025) Venetoclax-based low-intensity chemotherapy in the salvage treatment of relapsed\/refractory T-cell acute lymphoblastic leukemia. Clin Exp Med 25(1):104","journal-title":"Clin Exp Med"},{"key":"6955_CR12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-191190","author":"SS Suo","year":"2023","unstructured":"Suo SS et al (2023) Venetoclax combined with Hag regimen in newly diagnosed ETP-ALL: interim analysis of a prospective, multicenter, phase 2 trial. Blood. https:\/\/doi.org\/10.1182\/blood-2023-191190","journal-title":"Blood"},{"issue":"3","key":"6955_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1182\/bloodadvances.2024014405","volume":"9","author":"MR Luskin","year":"2025","unstructured":"Luskin MR et al (2025) Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia. Blood Adv 9(3):617\u2013626","journal-title":"Blood Adv"},{"issue":"4","key":"6955_CR14","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1182\/bloodadvances.2023012231","volume":"8","author":"NJ Short","year":"2024","unstructured":"Short NJ et al (2024) A phase 1\/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed\/refractory acute lymphoblastic leukemia. Blood Adv 8(4):909\u2013915","journal-title":"Blood Adv"},{"issue":"8","key":"6955_CR15","first-page":"649","volume":"44","author":"JY Kong","year":"2023","unstructured":"Kong JY et al (2023) Clinical efficacy and safety of venetoclax combined with multidrug chemotherapy in the treatment of 15 patients with relapsed or refractory early T-cell precursor acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi 44(8):649\u2013653","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"4","key":"6955_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","volume":"20","author":"G Richard-Carpentier","year":"2020","unstructured":"Richard-Carpentier G et al (2020) Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory t-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 20(4):212\u2013218","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"6955_CR17","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1080\/10428194.2021.1897807","volume":"62","author":"S Arora","year":"2021","unstructured":"Arora S et al (2021) Venetoclax with chemotherapy in relapse\/refractory early T-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma 62(9):2292\u20132294","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"6955_CR18","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA et al (2021) Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov 11(6):1440\u20131453","journal-title":"Cancer Discov"},{"key":"6955_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1358161","volume":"11","author":"Y Jiang","year":"2024","unstructured":"Jiang Y et al (2024) Case report: treatment of two cases of recurrent\/refractory early T-cell precursor acute lymphoblastic leukemia with venetoclax combined with the CAG regimen. Front Med (Lausanne) 11:1358161","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"6955_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/MPH.0000000000002672","volume":"45","author":"P Borah","year":"2023","unstructured":"Borah P et al (2023) Short-course venetoclax with standard chemotherapy is effective in early T-cell precursor acute lymphoblastic leukemia. J Pediatr Hematol Oncol 45(5):271\u2013274","journal-title":"J Pediatr Hematol Oncol"},{"key":"6955_CR21","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00127","author":"Y Numan","year":"2018","unstructured":"Numan Y et al (2018) First report of clinical response to venetoclax in early T-cell precursor acute lymphoblastic leukemia. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.18.00127","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"6955_CR22","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.hemonc.2019.10.002","volume":"14","author":"N Farhadfar","year":"2021","unstructured":"Farhadfar N et al (2021) Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: a case report and review of literature. Hematol Oncol Stem Cell Ther 14(3):246\u2013251","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"4","key":"6955_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s12185-023-03623-w","volume":"118","author":"Y Zhao","year":"2023","unstructured":"Zhao Y et al (2023) Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review. Int J Hematol 118(4):483\u2013488","journal-title":"Int J Hematol"},{"issue":"2","key":"6955_CR24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00277-019-03902-9","volume":"99","author":"X Zhang","year":"2020","unstructured":"Zhang X et al (2020) Relapsed\/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen. Ann Hematol 99(2):395\u2013397","journal-title":"Ann Hematol"},{"issue":"3","key":"6955_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000379","volume":"4","author":"A McEwan","year":"2020","unstructured":"McEwan A, Pitiyarachchi O, Viiala N (2020) Relapsed\/refractory ETP-ALL successfully treated with venetoclax and nelarabine as a bridge to allogeneic stem cell transplant. Hemasphere 4(3):e379","journal-title":"Hemasphere"},{"issue":"10","key":"6955_CR26","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1002\/ccr3.3041","volume":"8","author":"E Zappone","year":"2020","unstructured":"Zappone E et al (2020) Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemia. Clin Case Rep 8(10):2000\u20132002","journal-title":"Clin Case Rep"},{"issue":"11","key":"6955_CR27","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1007\/s00277-022-04912-w","volume":"101","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Dai Y, Tang X (2022) Venetoclax combined with decitabine and HAAG regimen: a novel salvage strategy for relapsed\/refractory T-cell acute lymphoblastic leukaemia. Ann Hematol 101(11):2525\u20132528","journal-title":"Ann Hematol"},{"issue":"12","key":"6955_CR28","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.medj.2024.07.018","volume":"5","author":"S Suo","year":"2024","unstructured":"Suo S et al (2024) Homoharringtonine synergizes with venetoclax in early T cell progenitor acute lymphoblastic leukemia: bench and bed. Med 5(12):1510-1524 e4","journal-title":"Med"},{"issue":"13","key":"6955_CR29","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1080\/10428194.2021.1957876","volume":"62","author":"CL Wan","year":"2021","unstructured":"Wan CL et al (2021) Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series. Leuk Lymphoma 62(13):3300\u20133303","journal-title":"Leuk Lymphoma"},{"key":"6955_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000630","author":"PR Tembhare","year":"2020","unstructured":"Tembhare PR et al (2020) Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-000630","journal-title":"J Immunother Cancer"},{"issue":"8","key":"6955_CR31","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1007\/s00277-024-05775-z","volume":"103","author":"H Shi","year":"2024","unstructured":"Shi H et al (2024) Daratumumab and venetoclax combined with CAGE for late R\/R T-ALL\/LBL patients: single-arm, open-label, phase I study. Ann Hematol 103(8):2993\u20133004","journal-title":"Ann Hematol"},{"key":"6955_CR32","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00172","author":"R La Starza","year":"2019","unstructured":"La Starza R et al (2019) Venetoclax and bortezomib in relapsed\/refractory early t-cell precursor acute lymphoblastic leukemia. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.19.00172","journal-title":"JCO Precis Oncol"},{"key":"6955_CR33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179192","author":"A Cabannes-Hamy","year":"2023","unstructured":"Cabannes-Hamy A et al (2023) Oncogenetic-driven targeted therapy for relapsed\/refractory T-cell acute lymphoblastic leukemia\u202f: a French ALL-target observatory report. Blood. https:\/\/doi.org\/10.1182\/blood-2023-179192","journal-title":"Blood"},{"key":"6955_CR34","doi-asserted-by":"crossref","unstructured":"Luca Pagliaro MG, Rosati R, Zamponi R, Carnevali R, Camb\u00f2 B, Bardelli V, Tragni K, Montanaro A, Messina M, Piciocchi A, Marsili G, Crea E, Ciceri F, Chiaretti S, Papayannidis C, Piccini M, Rambaldi A, Sica S, Zappasodi P, La Starza R, Mecucci C, Roti G (2025) Advancing chemogenomic strategies for functional precision medicine in relapsed\/refractory t-all and ETP-ALL: preliminary results of the gimema ALL2720 trial","DOI":"10.21203\/rs.3.rs-8620646\/v1"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06955-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06955-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06955-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:59:12Z","timestamp":1776405552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06955-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6955"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06955-9","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from both patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from both patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"N\/A","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}},{"value":"N\/A","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}}],"article-number":"223"}}